Introduction {#S0001}
============

Transient hyperglycaemia (TH) may occur during the treatment of proliferative diseases of the haematopoietic system and severe aplastic anaemia. The TH is usually connected with administration of glucocorticosteroids, but other diabetogenic factors, such as L-asparaginase, are also used in the treatment of acute lymphoblastic leukaemia \[[@CIT0001]--[@CIT0003]\]. The incidence of hyperglycaemia in the course of steroid administration ranges according to various authors from 16% to 35% in paediatric haematological diseases \[[@CIT0004], [@CIT0005]\]. The negative influence of hyperglycaemia on the human immune system is well acknowledged \[[@CIT0006], [@CIT0007]\]. In children undergoing immunosuppressive treatment hyperglycaemia may represent a significant risk factor for a life-threatening infection. Considering the high incidence of hyperglycaemia and threats it poses for the haematological patients, early diagnosis and the introduction of adequate treatment should be prioritised. However, TH-related ketoacidosis is infrequent; therefore diagnosis based on clinical symptoms is difficult or simply impossible \[[@CIT0001]\]. Only an active search for hyperglycaemia in patients receiving glucocorticosteroid therapy enables diagnosis and introduction of appropriate treatment allowing for reduction of hyperglycaemia negative effects. We postulate that the majority of hyperglycaemic incidents in oncohaematological patients treated with glucocorticosteroids remain undiagnosed. The improvement of TH detection may constitute the first step towards the reduction of unfavourable consequences of hyperglycaemia in this group \[[@CIT0008]\]. The aim of this study was to work out a detailed protocol for carbohydrate metabolism control and to evaluate whether the protocol influences the frequency of diagnosed incidents of carbohydrate metabolism disturbances in children treated for acute lymphoblastic leukaemia (ALL), non-Hodgkin lymphoma (NHL) and severe aplastic anaemia (SAA).

Material and methods {#S0002}
====================

The study group included 128 children treated due to proliferative diseases of the haematopoietic system and severe aplastic anaemia in the Department of Paediatrics, Haematology, Oncology and Endocrinology at the Medical University of Gdansk from October 2005 to December 2010. The only inclusion criterion was the use of glucocorticosteroids in the therapeutic protocol. The detailed data on drugs used in individual therapeutic protocols, total doses per m^2^ of body surface and numbers of chemotherapy cycles with steroids in each protocol are presented in [Table I](#T0001){ref-type="table"}. All patients were divided into two groups. Group I consisted of 70 children treated from October 2005 to October 2008, in whom random blood glucose was evaluated as the only parameter (retrospective analysis). Group II consisted of 58 children treated from October 2008 to December 2010, in whom a programme of intensive carbohydrate metabolism control was implemented (prospective analysis). In all the patients in group II, the following data were assessed prior to steroid administration: family history of diabetes mellitus, body mass index (BMI) and levels of insulin, C-peptide, and glycosylated haemoglobin (HbA~1c~). The glucose tolerance test was not performed due to patients' general condition caused by their primary disease. All patients in group II had the fasting blood glucose checked daily during the glucocorticosteroid administration period, and in the subgroup of higher risk when fasting blood glucose was abnormal -- blood glucose was regularly evaluated after meals. The subgroup of higher risk consisted of patients who fulfilled at least one of the following criteria: C-peptide \< 0.9 or \> 2.5 ng/ml, fasting insulin \< 3 or \> 15 mU/l, family history of diabetes mellitus or obesity in first- or second-degree relatives and BMI \> the 95^th^ percentile. Whenever any disturbances in carbohydrate metabolism were noted, infusion fluids with glucose were discontinued, a reduced carbohydrate diet was introduced and blood glucose was monitored systematically (before breakfast and 2 h after main meals). When diabetes mellitus was diagnosed, insulin was started (basic or intensive insulin therapy). Three therapeutic management protocols were developed for children on glucocorticosteroids, named A, B, and C. Protocol A was applied in the cases where glucocorticosteroids were introduced for the first time or there were no carbohydrate metabolism disturbances (CHMD) observed in the previous cycle ([Figure 1](#F0001){ref-type="fig"}). If there had been CHMD in the first cycle, protocol B was applied in the next one. In the cases of CHMD in any of the two subsequent glucocorticosteroid cycles, protocol C was used ([Figure 2](#F0002){ref-type="fig"}).

![Protocol A for paediatric patients treated for proliferative diseases of the haematopoietic system and severe aplastic anaemia after first introduction of glucocorticosteroids or without carbohydrate metabolism disorders in the previous treatment cycle](AMS-8-19273-g001){#F0001}

![Protocol B and C for paediatric patients treated for proliferative diseases of the haematopoietic system and severe aplastic anaemia. Protocol B was applied for children with carbohydrate metabolism disorders in the first cycle; protocol C was applied for children with carbohydrate metabolism disorders in two subsequent cycles](AMS-8-19273-g002){#F0002}

###### 

Chemotherapy protocols used in the analysed patients in regard to total steroid dose, drug type and number of cycles with steroids

  Chemotherapy protocol                     Total dose of steroids in chemotherapy protocol \[mg/m^2^\] and type of drug   Number of chemotherapy cycles with steroids
  ----------------------------------------- ------------------------------------------------------------------------------ ---------------------------------------------
  ALL IC-BFM 2002 standard-risk             Prednisone 1740 mg/m^2^; Dexamethasone                                         2
  group arm and intermediate-risk           236.25 mg/m^2^                                                                 
  group arm                                                                                                                
  ALL IC-BFM 2002 high-risk group           Prednisone 1740 mg/m^2^; Dexamethasone                                         7
  arm A and B                               600 mg/m^2^                                                                    
  ALL-REZ BFM 2002                          Dexamethasone 500-700 mg/m^2^                                                  5-7
  B-NHL BFM 04 (arm: 2, 3 and 4)            Dexamethasone 100-490 mg/m^2^                                                  2-7
  Other[\*](#TF0001){ref-type="table-fn"}   Prednisone 210-1740 mg/m^2^; Dexamethasone 236.25-500 mg/m^2^                  2-6

ALCL 99, Euro-LB02, Interfant-06, WPSAA

Group I and II were compared in regard to age, sex, BMI, primary diagnosis, and applied therapeutic protocols. The total number of therapeutic cycles with glucocorticosteroids was calculated for both groups. The incidence of hyperglycaemia in both groups was comparatively analyzed. Next, the number of hyperglycaemic incidents per individual therapeutic protocol was analyzed in regard to the number of cycles with glucocorticosteroids. The fact that some children in group II were also given L-asparaginase according to the therapeutic protocol was also taken into consideration; we compared the incidence of hyperglycaemia in those who received the drug to those who did not.

The research was approved by the Independent Bioethics Committee for Scientific Research of the Medical University of Gdansk.

Statistical analysis {#S20007}
--------------------

All the patients' data and results were encoded and analysed using Microsoft Excel 2007 (Microsoft Inc, USA). The data showing normal distribution were compared using Student\'s t-test. Other data were analyzed with non-parametric tests (Mann-Whitney U test). Categorical values were compared using Pearson\'s χ^2^ test with the Yates correction or Fisher\'s exact test when applicable. Statistical analysis was carried out with SPSS v. 13.0 (SPSS Inc., USA) statistical software.

Results {#S0003}
=======

The age, sex distribution, BMI percentile, primary diagnosis and therapeutic protocols did not differ between the groups ([Table II](#T0002){ref-type="table"}). Four out of 70 patients from group I (5.7%) (before introducing the programme of CHMD control) had hyperglycaemia diagnosed during the treatment of the primary disease with glucocorticosteroid including protocols. In group II, for which CHMD control was applied, hyperglycaemia was diagnosed in 13/58 patients (22.4%). The differences in the incidence of hyperglycaemia between the two studied groups was statistically significant (*p* = 0.008). A total of 209 therapeutic cycles with administration of glucocorticosteroids were carried out in group I, with on average 3 cycles (SD 1.8; range 1-7) per patient, and 165 therapeutic cycles were carried out in group II, with on average 2.9 therapeutic cycles (SD 2.1; range 1-8) per patient (*p* = 0.209). In group I 5 hyperglycaemic incidents were diagnosed in the course of 209 cycles including glucocorticosteroids (2.4%), whereas in group II 30 hyperglycaemic incidents were diagnosed in over 165 cycles (18.2%). The detection of hyperglycaemia in group II was significantly higher (*p* \< 0.001). The incidence of hyperglycaemia in regard to the primary disease therapeutic protocol is presented in [Table III](#T0003){ref-type="table"}. Higher incidence of hyperglycaemia was observed in group II, i.e. in children included in the programme of CHMD early detection. Statistical significance was observed for patients who were treated with the ALL IC-BFM 2002 protocol for the high-risk group (arm A and B), the treatment protocol for recurrent acute lymphoblastic leukaemia (ALL-REZ BFM 2002), and in a heterogeneous group of children in whom protocols ALCL 99, Euro-LB02, Interfant-06 and WPSAA were used (*p* was 0.042, 0.021 and 0.002 respectively). Moreover, the incidence of hyperglycaemia did not differ significantly between the group of children treated with protocols including L-asparaginase and the group of children not receiving this drug (19% vs. 50%; *p* = 0.119).

###### 

Comparison of the studied groups in regard to age, sex, diagnoses and applied chemotherapy protocols

  Feature                                                                     Group I       Group II      Value of *p*
  --------------------------------------------------------------------------- ------------- ------------- --------------
  Age (median (SD))                                                           6.24 (4.38)   5.42 (4.46)   0.705
  BMI percentile (mean (SD))                                                  41.7 (34.7)   33.5 (35)     0.772
  Gender:                                                                     0.183                       
  • Male                                                                      34            35            
  • Female                                                                    36            23            
  Diagnosis:                                                                                              0.751
  • ALL                                                                       52            42            
  • ALL recidiva                                                              4             6             
  • ALCL                                                                      3             0             
  • NHL B cell                                                                7             6             
  • NHL T cell                                                                1             1             
  • NHL recidiva                                                              1             1             
  • SAA                                                                       2             2             
  Chemotherapy protocol:                                                      0.775                       
  • ALL IC-BFM 2002 standard-risk group arm and intermediate-risk group arm   41            35            
  • ALL IC-BFM 2002 high-risk group arm A and B                               9             5             
  • ALL-REZ BFM 2002                                                          4             6             
  • B-NHL BFM 04 (arm: 2, 3 and 4)                                            7             4             
  • Other[\*](#TF0002){ref-type="table-fn"}                                   9             8             

ALCL 99, Euro-LB02, Interfant-06, WPSAA; SD -- standard deviation, BMI -- body mass index, ALL -- acute lymphoblastic leukaemia, ALCL -- anaplastic large cell lymphoma, NHL -- non-Hodgkin lymphoma, SAA -- severe aplastic anaemia

###### 

Comparison of the studied groups in regard to the incidence of hyperglycaemia depending on the applied therapeutic protocol

  Chemotherapy protocol                                                     Incidence of hyperglycaemia   Group I   Group II   Value of *p*
  ------------------------------------------------------------------------- ----------------------------- --------- ---------- --------------
  ALL IC-BFM 2002 standard-risk group arm and intermediate-risk group arm   Yes                           1         2          0.582
                                                                            No                            77        59         
  ALL IC-BFM 2002 high-risk group arm A and B                               Yes                           3         7          0.042
                                                                            No                            47        25         
  ALL-REZ BFM 2002                                                          Yes                           1         13         0.021
                                                                            No                            19        25         
  B-NHL BFM 04 (arm: 2, 3 and 4)                                            Yes                           0         2          0.106
                                                                            No                            32        14         
  Other[\*](#TF0003){ref-type="table-fn"}                                   Yes                           0         6          0.002
                                                                            No                            29        12         

ALCL 99, Euro-LB02, Interfant-06, WPSAA

Discussion {#S0004}
==========

Numerous reports confirm the unfavourable impact of hyperglycaemia on the course of therapy in patients with life-threatening conditions \[[@CIT0008], [@CIT0009]\]. In parallel they indicate that better therapeutic effects can be achieved owing to meticulous blood glucose control \[[@CIT0002], [@CIT0003], [@CIT0008]--[@CIT0013]\]. Many authors emphasize the unfavourable influence of hyperglycaemia on the immune system in humans \[[@CIT0006], [@CIT0014]\]. Children treated for proliferative diseases of the haematopoietic system and severe aplastic anaemia are especially exposed to life-threatening infections. New predictors of the final prognosis in these patients are still being sought \[[@CIT0015]\]. Neutropenia, as is well established, is the most significant risk factor for infection in this group \[[@CIT0016]\]. Hyperglycaemia could however be an accumulative and underestimated infection risk factor, especially in children. Therapeutic protocols applied in paediatric oncohaematology lack detailed guidelines regarding CHMD monitoring. Since the typical symptoms of ketoacidosis are absent, many episodes of hyperglycaemia in children treated with glucocorticosteroids remain unnoticed and undiagnosed \[[@CIT0001], [@CIT0017]\]. Literature data on hyperglycaemia frequency in this group of patients vary; frequency of 4% to 22.2% was reported \[[@CIT0001], [@CIT0003], [@CIT0013], [@CIT0016], [@CIT0017]\]. Most of the cited studies were based on retrospective analysis. The data presented in this paper come from a prospectively designed study. Our results, showing significantly higher incidence of diabetes in children included in the programme for early CHMD diagnosis, seem to confirm the hypothesis. It also seems important to preselect a group of patients with a high risk of developing TH within the children treated for proliferative diseases of the haematopoietic system and severe aplastic anaemia.

The algorithm of diagnostic and therapeutic management formulated in this study includes the evaluation of early risk of diabetes development as well as previous incidents of diabetes in preceding chemotherapy cycles. The simple criteria applied, including medical history, BMI evaluation and preliminary assessment of C-peptide level, glucose concentration and glycosylated haemoglobin level, enable planning CHMD control in individual patients. The algorithm allows for early diagnosis and implementation of appropriate therapeutic measures. It may go a long way towards reducing the number of negative effects of hyperglycaemia in the analysed group. The algorithm is simple and uncomplicated, and requires no specialist equipment or financial expenditures.

In conclusion, the protocols of early detection of carbohydrate metabolism disturbances formulated here may be useful in all children on chronic treatment with glucocorticosteroids, not only in those with haematopoietic system diseases, as it seems that also in these children some hyperglycaemia episodes remain undiagnosed. The analysis of how L-asparaginase impacts the incidence of hyperglycaemia showed no statistically significant differences when groups of children receiving or not receiving the drug were compared. However, prospective studies including larger groups are required. Another advantage of the protocol applied here is the opportunity to select a group of children who may develop diabetes in the future. These children must be followed up in the Diabetes Outpatient Clinic after termination of their antineoplastic therapy. The next expected effect of the protocol formulated here is the reduction of the number of infections in children treated for diseases of the haematopoietic system. Prospective studies are required to demonstrate the influence of normal carbohydrate metabolism on the frequency of infectious complications in this group.
